SecBot SecBot
8-K ·Filed Sep 15, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001140361-26-036563
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

This is a major regulatory de-risking for RCKT's lead cardiovascular gene therapy program. The clear path to a 12-patient pivotal study with preserved accelerated approval endpoints removes significant uncertainty. Traders should watch for the October 6, 2026 webinar for further data updates and monitor enrollment progress toward the mid-2027 dosing completion target.

DirectionBullish
Confidencehigh
Horizonweeks

RP-A501

● Neutral Named in this 8-K
Impact
Phase
Phase 2 (pivotal/registrational)
Time to market
If the pivotal Phase 2 trial succeeds, a BLA submission for accelerated approval could follow in 2028-2029, given the 12-month endpoint timeline with last patient dosed by mid-2027.
Next catalyst
None dated

What to watchWatch for updates on enrollment of the remaining 9 patients in the pivotal Phase 2 trial and any interim data presentations at medical conferences in 2027. The FDA alignment in September 2026 de-risked the regulatory path, but the stock near its 52-week low reflects lingering safety concerns and a long wait until topline data (likely 2028). KRESLADI commercial traction is a separate value driver that could support the stock in the interim.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$3.41
T+0 close · Sep 15, 2026 · via day close
Latest settled
−32.55%
T+20 · $2.30 · next T+60 in 22d
Vs SPY
−35.27%
α at T+20
Latest observation
−28.72%
T+43 · FF3 residual α
  1. T+0 · Sep 15 $3.41entry
  2. T+1 · 2mo ago +2.05%α +2.49% · $3.48
  3. T+5 · 8w ago −1.76%α −3.89% · $3.35
  4. T+20 · 5w ago −32.55%α −35.27% · $2.30
  5. T+44 · todayOpen
  6. T+60 · in 22d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rocket Pharmaceuticals announced FDA alignment on the path to complete the pivotal Phase 2 trial of RP-A501 for Danon disease. The FDA confirmed a 12-patient pivotal population at a recalibrated dose, with the first three patients already treated counting toward that total, and preserved 12-month co-primary endpoints intended to support potential accelerated approval. This removes a key regulatory overhang and provides a clear path to enrollment completion by mid-2027, a significant de-risking event for the program.

Key Facts

  • FDA confirmed continued enrollment and dosing under the modified protocol at the recalibrated dose of 3.8 × 10^13 GC/kg.
  • Pivotal study population set at 12 male patients; first three patients treated count toward this total, leaving nine to enroll.
  • Rocket expects to complete dosing of remaining patients by mid-2027.
  • Co-primary endpoints of myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index at 12 months are preserved to support potential accelerated approval.
  • No clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome observed in the first three patients.
  • A comprehensive Danon disease program webinar is scheduled for October 6, 2026.

Financial Impact

No financial data provided in the filing. The event de-risks a pivotal gene therapy program for Danon disease, a rare and life-threatening condition with no approved therapies, representing a potential multi-hundred-million to billion-dollar peak sales opportunity if approved.

Risk Factors

  • The pivotal trial is small (12 patients) and efficacy/safety results remain binary; a miss on co-primary endpoints at 12 months would be devastating.
  • Manufacturing scale-up for commercial-grade product and long-term durability of LAMP2 expression are unproven.
  • The company is pre-revenue and will require additional capital to fund operations through potential approval.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-036563
Document: ef20082010_ex99-1.htm0001140361-26-036563
Document: 0001140361-26-036563-index-headers.html0001140361-26-036563
Document: 0001140361-26-036563-index.html0001140361-26-036563
Document: 0001140361-26-036563.txt0001140361-26-036563

Track record

21 reports on RCKT

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  3. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  5. Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
  7. Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
  8. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
  9. Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
  10. Sep 15, 20268w ago 8-K Bullish 7/10 Viewing Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 15, 2026